US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

33.73

-0.8400-2.43%

Post-market: 33.730.00000.00%17:06 EDT

Volume:288.05K

Turnover:9.93M

Market Cap:949.37M

PE:-19.06

High:35.49

Open:35.35

Low:33.65

Close:34.57

Loading ...

Overview Company News Filings

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tvardi Therapeutics Initiated at Overweight by Cantor Fitzgerald

Press Release: Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target

MT Newswires Live

MiNK Therapeutics announces publication of complete remission using agenT-797

Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target

MT Newswires Live

Janux Therapeutics initiated with an Outperform at Raymond James

Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified

Amplia Therapeutics Reports Promising Response in Pancreatic Cancer Trial

MT Newswires Live

Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial

Century Therapeutics Files $200 Million Mixed Shelf

MT Newswires Live

Ovid Therapeutics Approves Key Proposals at Annual Meeting

Relmada Therapeutics Ends Esmethadone License Agreement

Century Therapeutics files $200M mixed securities shelf

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

CRISM Therapeutics Announces Change in Major Holdings

NeuroSense Therapeutics Releases Q2 2025 Corporate Update

NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital

AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":33.73,"timestamp":1752868800000,"preClose":34.57,"halted":0,"volume":288046,"hourTrading":{"tag":"盘后","latestPrice":33.73,"preClose":33.73,"latestTime":"17:06 EDT","volume":775,"amount":26162.6,"timestamp":1752872785598},"delay":0,"floatShares":12538526,"shares":28146154,"eps":-1.769251,"marketStatus":"Market Closed","change":-0.84,"latestTime":"07-18 16:00:00 EDT","open":35.35,"high":35.485,"low":33.645,"amount":9926090.220002001,"amplitude":0.053225,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.769251,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":34.57,"preHourTrading":{"tag":"盘前","latestPrice":35.3,"preClose":34.57,"latestTime":"09:29 EDT","volume":499,"amount":17604.058825,"timestamp":1752845399999},"postHourTrading":{"tag":"盘后","latestPrice":33.73,"preClose":33.73,"latestTime":"17:06 EDT","volume":775,"amount":26162.6,"timestamp":1752872785598},"volumeRatio":0.8035328724389679,"impliedVol":1.0249,"impliedVolPercentile":0.8986},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":12538526,"roa":"-17.75%","roe":"-24.47%","lyrEps":-2.338654,"volumeRatio":0.8035328724389679,"shares":28146154,"dividePrice":0,"high":35.485,"amplitude":0.053225,"preClose":34.57,"low":33.645,"week52Low":16.535,"pbRate":"4.94","week52High":38.93,"institutionHeld":0,"latestPrice":33.73,"eps":-1.769251,"divideRate":0,"volume":288046,"delay":0,"ttmEps":-1.769251,"open":35.35,"prevYearClose":28.87,"prevWeekClose":34.69,"prevMonthClose":29.31,"prevQuarterClose":29.31,"fiveDayClose":34.69,"twentyDayClose":30.03,"sixtyDayClose":25.79},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550554729","title":"Aligos Therapeutics announces inducement grants under Nasdaq listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2550554729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550554729?lang=en_us&edition=fundamental","pubTime":"2025-07-11 20:35","pubTimestamp":1752237321,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to pur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALGS","BK4585","USJW.SI","LU2095319765.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD",".IXIC","BK4112","QLD","BK4505","IE00BKPKM429.USD","BK4139","TSYW.SI","IE00B64PRP62.GBP","NVIW.SI","QID","LENZ","USAW.SI","MNQmain","BK4539","TQQQ","IE00BGHQF748.EUR","SQQQ","BK4588","BK4007","PSQ","LU2210150020.SGD","NQmain"],"gpt_icon":0},{"id":"2550678955","title":"Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550678955","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550678955?lang=en_us&edition=fundamental","pubTime":"2025-07-11 20:30","pubTimestamp":1752237000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., July  11, 2025  (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/11/3113985/0/en/Aligos-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4505","BK4585","ALGS","LENZ","LU2095319765.USD","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","NDAQ","IE00BKPKM429.USD","BK4588",".IXIC","LU2210149790.SGD","BK4112","BK4139","BK4539","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2550953126","title":"Tvardi Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2550953126","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550953126?lang=en_us&edition=fundamental","pubTime":"2025-07-11 20:11","pubTimestamp":1752235860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 08:11 ET (12:11 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","LENZ"],"gpt_icon":0},{"id":"2550958958","title":"Press Release: Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2550958958","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550958958?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:43","pubTimestamp":1752234180,"startTime":"0","endTime":"0","summary":"Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025. SOUTH SAN FRANCISCO & BOSTON, July 11, 2025  -- Helix Acquisition Corp. II  , a special purpose acquisition company  sponsored by Cormorant Asset Management, and TheRas, Inc.  , a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K<ALPHA> malignancies, today announced that the registration statement on Form S-4  , filed by Helix and BBOT, relating to the previously-announced business combination among Helix, BBOT, and the other parties thereto , has been declared effective by the U.S. Securities and Exchange Commission .The parties anticipate that the Business Combination will close in August 2025, subject to satisfaction of the conditions to the closing of the Business Combination.BridgeBio Oncology Therapeutics  is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139","HLXB"],"gpt_icon":0},{"id":"2550958523","title":"Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2550958523","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550958523?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:36","pubTimestamp":1752233817,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics (TVRD) has an average rating of buy and mean price target of $55.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TVRD"],"gpt_icon":0},{"id":"2550581319","title":"MiNK Therapeutics announces publication of complete remission using agenT-797","url":"https://stock-news.laohu8.com/highlight/detail?id=2550581319","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550581319?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:35","pubTimestamp":1752233720,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced the publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-announces-publication-of-complete-remission-using-agent-797-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-announces-publication-of-complete-remission-using-agent-797-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139","INKT"],"gpt_icon":0},{"id":"2550302329","title":"Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2550302329","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550302329?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:21","pubTimestamp":1752232918,"startTime":"0","endTime":"0","summary":"Janux Therapeutics (JANX) has an average rating of buy and mean price target of $86.58, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JANX","LENZ","RJF"],"gpt_icon":0},{"id":"2550930809","title":"Janux Therapeutics initiated with an Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2550930809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550930809?lang=en_us&edition=fundamental","pubTime":"2025-07-11 18:50","pubTimestamp":1752231027,"startTime":"0","endTime":"0","summary":"Raymond James analyst Sean McCutcheon initiated coverage of Janux Therapeutics (JANX) with an Outperform rating and $65 price target Janux is clini...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/janux-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/janux-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","LENZ","JANX"],"gpt_icon":0},{"id":"2550093789","title":"Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified","url":"https://stock-news.laohu8.com/highlight/detail?id=2550093789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550093789?lang=en_us&edition=fundamental","pubTime":"2025-07-11 18:36","pubTimestamp":1752230167,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joori Park has reiterated their bullish stance on LRMR stock, giving a Buy rating on July 8. Joori Park’s rating is based ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-larimar-therapeutics-nomlabofusp-in-friedreichs-ataxia-a-buy-rating-justified-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-larimar-therapeutics-nomlabofusp-in-friedreichs-ataxia-a-buy-rating-justified-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2550670235","title":"Amplia Therapeutics Reports Promising Response in Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2550670235","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550670235?lang=en_us&edition=fundamental","pubTime":"2025-07-11 09:01","pubTimestamp":1752195693,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  reported an additional confirmed partial response in its ongoing ACCENT clinical trial evaluating the focal adhesion kinase inhibitor narmafotinib alongside standard chemotherapy, according to a Friday Australian bourse filing.A confirmed partial response is defined as a tumor shrinkage exceeding 30%, sustained for at least two months, with no new lesions detected, the filing said.The update lifts the objective response rate to 31%, surpassing the 23% benchmark seen with chemotherapy alone, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4007","LENZ","BK7067","ATX.AU"],"gpt_icon":0},{"id":"2550312672","title":"Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2550312672","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550312672?lang=en_us&edition=fundamental","pubTime":"2025-07-11 07:38","pubTimestamp":1752190689,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics ( ($AU:ATX) ) just unveiled an update. Amplia Therapeutics has announced a new partial response in its ongoing ACCENT trial for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amplia-therapeutics-reports-positive-results-in-pancreatic-cancer-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amplia-therapeutics-reports-positive-results-in-pancreatic-cancer-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2550679750","title":"Century Therapeutics Files $200 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2550679750","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550679750?lang=en_us&edition=fundamental","pubTime":"2025-07-11 05:38","pubTimestamp":1752183515,"startTime":"0","endTime":"0","summary":"Century Therapeutics (IPSC) filed a registration statement Thursday for the sale of up to $200 million of its securities from time to time in one or more offerings.The filing covers common stock, preferred stock, debt securities, warrants, units and subscription rights, according to the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4505","LENZ","BK4007","BK4139","IPSC","CNBKA"],"gpt_icon":0},{"id":"2550799776","title":"Ovid Therapeutics Approves Key Proposals at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2550799776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550799776?lang=en_us&edition=fundamental","pubTime":"2025-07-11 05:03","pubTimestamp":1752181405,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics ( ($OVID) ) has provided an update. On July 9, 2025, Ovid Therapeutics held its annual stockholders meeting, where several key pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ovid-therapeutics-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ovid-therapeutics-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2550679331","title":"Relmada Therapeutics Ends Esmethadone License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2550679331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550679331?lang=en_us&edition=fundamental","pubTime":"2025-07-11 05:01","pubTimestamp":1752181265,"startTime":"0","endTime":"0","summary":"An announcement from Relmada Therapeutics ( ($RLMD) ) is now available. Relmada Therapeutics announced the termination of its License Agreement wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/relmada-therapeutics-ends-esmethadone-license-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/relmada-therapeutics-ends-esmethadone-license-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2550967938","title":"Century Therapeutics files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2550967938","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550967938?lang=en_us&edition=fundamental","pubTime":"2025-07-11 04:55","pubTimestamp":1752180908,"startTime":"0","endTime":"0","summary":"16:51 EDT Century Therapeutics (IPSC) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/century-therapeutics-files-200m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/century-therapeutics-files-200m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4505","BK4139","CNBKA","LENZ","IPSC","BK4539"],"gpt_icon":0},{"id":"2550867524","title":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2550867524","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550867524?lang=en_us&edition=fundamental","pubTime":"2025-07-11 04:10","pubTimestamp":1752178200,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, July  10, 2025  (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/10/3113679/0/en/Serina-Therapeutics-Makes-Grant-to-New-Employee-Under-Inducement-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2550862997","title":"CRISM Therapeutics Announces Change in Major Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2550862997","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550862997?lang=en_us&edition=fundamental","pubTime":"2025-07-10 22:07","pubTimestamp":1752156441,"startTime":"0","endTime":"0","summary":"Amur Minerals ( ($GB:CRTX) ) has provided an announcement. CRISM Therapeutics Corporation, a UK-based issuer, has announced a change in major holdi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-announces-change-in-major-holdings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-announces-change-in-major-holdings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2550626245","title":"NeuroSense Therapeutics Releases Q2 2025 Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2550626245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550626245?lang=en_us&edition=fundamental","pubTime":"2025-07-10 21:49","pubTimestamp":1752155340,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics Ltd. ( ($NRSN) ) has provided an update. On July 10, 2025, NeuroSense Therapeutics Ltd. released a corporate video titled ‘...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurosense-therapeutics-releases-q2-2025-corporate-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurosense-therapeutics-releases-q2-2025-corporate-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2550628377","title":"NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2550628377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550628377?lang=en_us&edition=fundamental","pubTime":"2025-07-10 20:36","pubTimestamp":1752150960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRSN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 10, 2025 08:36 ET (12:36 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","LENZ"],"gpt_icon":0},{"id":"2550640285","title":"AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2550640285","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550640285?lang=en_us&edition=fundamental","pubTime":"2025-07-10 20:26","pubTimestamp":1752150360,"startTime":"0","endTime":"0","summary":"AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.AbbVie on Thursday said it will pay $700 million up front for an exclusive license to IGI's ISB 2001, a trispecific T-cell engager developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.AbbVie said it will have exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, Japan and Greater China, with IGI eligible to receive up to $1.225 billion in development, regulatory and commercial milestone payments, along with royalties on product sales.IGI Therapeutics is a unit of New York-based Ichnos Glenmark Innovation, an alliance launched last year by India's Glenmark Pharmaceuticals and its Ichnos Sciences unit.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550494.USD","LU1267930490.SGD","LU1983299246.USD","LU1037948541.HKD","SG9999001440.SGD","LU0029864427.USD","LU1093756325.SGD","IGI","LU0320765646.SGD","LU1267930573.SGD","LU0256863902.USD","LU0661504455.SGD","LU1003077747.HKD","LU1244550221.USD","SG9999003800.SGD","SG9999011175.SGD","LU0545039389.USD","LU0708994859.HKD","LU1162221912.USD","LU1989772840.SGD","LU2468319806.SGD","LU1839511570.USD","LU0456855351.SGD","LU2129689605.HKD","IE00BFTCPJ56.SGD","LU0158827948.USD","LU0795875169.SGD","LU0170899867.USD","BK4581","LU0256863811.USD","LU1037948897.HKD","LU0795875086.SGD","LU0689472784.USD","LU0985320562.USD","BK4534","LU0211328371.USD","IE0002270589.USD","SG9999015986.USD","LU0949170772.SGD","ABBV","LU1718418525.SGD","LU0738911758.USD","LENZ","LU0965508806.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU2237443382.USD","SG9999015952.SGD","LU1496350171.SGD","IE0009355771.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-07-17","current":-20.747029,"percent":0,"low":-20.747029,"twenty":-15.811799,"median":-10.788339,"eighty":-7.479638,"high":-5.069183,"avg":-11.383781,"sd":4.077823,"marketCap":990463159},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-17","current":-20.747029,"twenty":-15.811799,"median":-10.788339,"eighty":-7.479638,"marketCap":990463159}],"updateTime":1752902791928}}}